Predictions
Urban Outfitters
Start price
Target price
Perf. (%)
€39.60
20.02.24
20.02.24
€40.64
20.02.25
20.02.25
-21.72%
11.09.24
11.09.24
Iovance Biotherapeutics Inc.
Start price
Target price
Perf. (%)
€10.58
20.02.24
20.02.24
€31.41
20.02.25
20.02.25
-20.96%
16:31
16:31
Delivery Hero SE
Start price
Target price
Perf. (%)
€22.95
19.02.24
19.02.24
€24.00
19.02.25
19.02.25
3.49%
06.03.24
06.03.24
Could be worthwhile Investment >10% per year
Market Leader or Top 3
Well known brand
Very Future proof/growth oriented business model
Fibrogen Inc.
Start price
Target price
Perf. (%)
€2.14
19.02.24
19.02.24
-
19.02.25
19.02.25
-24.30%
03.03.24
03.03.24
Probably not worthwhile Investment
Fibrogen Inc.
Start price
Target price
Perf. (%)
€2.14
19.02.24
19.02.24
€6.00
31.07.27
31.07.27
-44.67%
26.05.24
26.05.24
Could be very worthwhile Investment >20% year
Under Armour Inc. C
Start price
Target price
Perf. (%)
€7.17
18.02.24
18.02.24
€7.00
18.02.25
18.02.25
4.18%
23.02.24
23.02.24
Revenue growth >5% per year expected
EBIT growth >5% per year expected
Higher EBIT margin than peer group
Fair valuation
LiveRamp Holdings, Inc.
Start price
Target price
Perf. (%)
€33.80
18.02.24
18.02.24
-
18.02.25
18.02.25
-35.50%
09.09.24
09.09.24
Nu Skin Enterprises A
Start price
Target price
Perf. (%)
€12.70
17.02.24
17.02.24
-
17.02.25
17.02.25
-43.98%
11.09.24
11.09.24
Ionis Pharmaceuticals Inc.
Start price
Target price
Perf. (%)
€41.07
17.02.24
17.02.24
-
17.02.25
17.02.25
-6.01%
11.09.24
11.09.24
Plastic Omnium S.A.
Start price
Target price
Perf. (%)
€10.44
17.02.24
17.02.24
-
17.02.25
17.02.25
5.56%
02.03.24
02.03.24
Could be worthwhile Investment >10% per year
Rheinmetall AG
Start price
Target price
Perf. (%)
€399.90
17.02.24
17.02.24
€400.00
17.02.25
17.02.25
2.83%
23.02.24
23.02.24
Could be worthwhile Investment >10% per year
Higher EBIT margin than peer group
positive Cash Flow expected
Good rating
Sixt SE ST
Start price
Target price
Perf. (%)
€86.65
17.02.24
17.02.24
€87.00
17.02.25
17.02.25
3.64%
04.03.24
04.03.24
EBIT growth >5% per year expected
Top Rating
Very valuable balance sheet
Normal challenges to pay loans and raise capital